Jyong Biotech Ltd. Ordinary Shares

NASDAQ:MENS

Biotechnology

Healthcare
$1.86 -1.41%

-$0.02 today

Market cap
$141.41M
Beta
2.08
P/E (TTM)
-25.1
EPS (TTM)
-$0.06
52W Low $1.43High $67.00

Volume 0.07M

Average 0.10M

MENS Operating Income

Profit from core operations after operating expenses, before interest and taxes.

Jyong Biotech Ltd. Ordinary SharesNASDAQ: MENS

Operating Income · Q4 FY2025 · quarter ended Dec 2025

Operating income remains negative

Q4 FY2025 operating income was -$1.79M, compared with -$552.5 a year earlier. Trailing-twelve-month operating income was -$2.06K.

Context

  • Operating income grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly operating income holds near -$1.79M or moves back toward the trailing-twelve-month quarterly average of -$514.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
-$1.79M— QoQ
Last fiscal yearDec 2025
-$2.61M-26.8% YoY
LTMDec 2024
-$2.06K— YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-324062.9%——
1 year-26.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Operating Income history

USD · from the income statement

Latest · FY2025
(2.61M) USD
Year-over-year change
-26.8%

Operating Income vs competitors

How MENS compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
MENS Competitors
Operating Income for MENS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LEGNLegend Biotech CorporationLTM Sep 2026$34.1M USD+117.9%—2.5%
MENSJyong Biotech Ltd. Ordinary SharesLTM Dec 2024-$2.06K USD———
TVTXTravere Therapeutics, Inc.LTM Sep 2026-$133.49M USD-46.5%—20.5%
CELCCelcuity Inc.LTM Jun 2026-$208.68M USD-42.3%——
CNTACentessa Pharmaceuticals plcLTM Mar 2026-$256.69M USD-31.1%——
CGONCG Oncology, Inc. Common stockLTM Sep 2026-$264.74M USD-47.0%—4293.5%
APGEApogee Therapeutics, Inc.LTM Jun 2026-$328.11M USD-21.2%——
XENEXenon Pharmaceuticals Inc.LTM Sep 2026-$465.32M USD-36.5%——
DYNDyne Therapeutics, Inc.LTM Jun 2026-$536.96M USD-21.8%——
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026-$561.78M USD-9.4%—83.9%
AAPGAscentage Pharma Group InternationalFY2025-CN¥1.18B CNY-218.9%—211.1%
Peer median (excluding MENS) —-33.8%—83.9%

Competitors are the stored peer set for MENS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue121K122K127K120K100K
Gross Profit(121K)(122K)(127K)(120K)(100K)
Gross Margin—————
Research & Development1.56M1.29M1.07M927K731K
Selling, General & Admin845K1.54M1.73M1.13M1.78M
Operating Expenses2.4M2.83M2.8M2.06M2.51M
Depreciation & Amortization122K123K127K120K100K
EBITDA(3.24M)(5.74M)(3.52M)(1.86M)(2.51M)
EBITDA Margin—————
Operating Income(2.4M)(2.83M)(2.8M)(2.06M)(2.61M)
Operating Margin—————
Interest Income6K5K56K7K610K
Interest Expense835K765K757K1.04M2.54M
Other Income / Expenses(1.79M)(3.8M)(1.6M)(963K)(2.06M)
Income Before Tax(4.2M)(6.63M)(4.4M)(3.02M)(4.67M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(4.2M)(6.63M)(4.4M)(3.02M)(4.67M)
Net Margin—————
EPS (Basic)(0.06)(0.09)(0.06)(0.04)(0.06)
EPS (Diluted)(0.06)(0.09)(0.06)(0.04)(0.06)
Weighted Avg Shares76.03M76.03M76.03M76.03M73.01M
Weighted Avg Shares (Diluted)76.03M76.03M76.03M76.03M73.01M

Jyong Biotech Ltd. Ordinary Shares

NASDAQ:MENS

Intrinsic Alpha fair value

Locked

Current Price

$1.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.